Patient demographics and oncology treatment history
| Patient | Age (yr) | Cancer Type | Prior Chemotherapy | Prior Chemotherapy Regimen | Adjuvant Chemotherapy |
|---|---|---|---|---|---|
| 1 | 33 | Recurrent Hodgkin lymphoma | Yes | ABVD | ICE followed by |
| cyclophosphamide (Cytoxan) and busulfan | |||||
| Autologous bone marrow transplant | |||||
| 2 | 32 | Recurrent Hodgkin lymphoma | Yes | CHOP/ABVD | Ara-C, vincristine, cisplatin |
| Danazol | |||||
| 3 | 11 | Brain stem medulloblastoma | No | – | Vincristine, VP-16, carboplatin |
| CCNU, cisplatin | |||||
| 4 | 60 | Recurrent gastric adenocarcinoma (stage IV) | No | – | 5-FU, leucovorin |
| 5 | 42 | Refractory acute lymphocytic leukemia | Yes | Hyper-CVAD | Intrathecal cytarabine |
| Methotrexate | Autologous bone marrow transplant | ||||
| 6-Mercaptopurine | |||||
| 6 | 41 | Hodgkin lymphoma | No | – | No |
| 7 | 29 | Brain stem glioma | No | – | TMZ |
| 8 | 28 | Recurrent Hodgkin lymphoma | Yes | ABVD | ICE followed by |
| cyclophosphamide and busulfan | |||||
| Autologous bone marrow transplant | |||||
| 9 | 33 | Recurrent Hodgkin lymphoma | Yes | ABVD | ICE followed by |
| cyclophosphamide and busulfan | |||||
| Brentuximab vedotin | |||||
| Autologous bone marrow transplant | |||||
| 10 | 37 | Recurrent Hodgkin lymphoma | Yes | ABVD | ICE followed by |
| cyclophosphamide and busulfan | |||||
| Autologous bone marrow transplant |
Note:—ABVD indicates doxorubicin, bleomycin, vinblastine, dacarbazine; CHOP, cyclophosphamide, doxorubicin hydrochloride, vincristine, prednisone; Hyper-CVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; TMZ, temozolomide; CCNU, lomustine; ICE, ifosfamide, carboplatin, etoposide chemotherapy protocol; Vp-16, etoposide phosphate.